Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1419-1428

  Cao, Longlong ^a,b   Zhou, Jiechao ^b   Zhang, Junrong ^a,b   Wu, Sijin ^c   Yang, Xintao ^a,b   Zhao, Xin ^b   Li, Huifang ^b   Luo, Ming ^a   Yu, Qian ^a   Lin, Guangtan ^a   Lin, Huizhong ^a   Xie, Jianwei ^a   Li, Ping ^a   Hu, Xiaoqing ^c   Zheng, Chaohui ^a   Bu, Guojun ^b   Zhang, Yun Wu ^b,d   Xu, Huaxi ^b,d,e   Yang, Yongliang ^c   Huang, Changming ^a   Zhang, Jie ^b,d   more..

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research Institute of Neuroscience College of Medicine   (China)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^d XIAMEN UNIVERSITY   (China)

^e BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 5; NS 0011; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; CDK5 PROTEIN, HUMAN; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN; MALEIMIDE DERIVATIVE; MESSENGER RNA; NS-0011; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG IDENTIFICATION; ENZYME LOCALIZATION; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GASTRIC CANCER CELL LINE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ISOTHERMAL TITRATION CALORIMETRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL TRANSFORMATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; STOMACH; STOMACH TUMOR; TUMOR CELL LINE;

AMINOPYRIDINES; ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 5; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KARYOPHERINS; LYMPHATIC METASTASIS; MALE; MALEIMIDES; MICE; MICE, INBRED BALB C; PROGNOSIS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; STOMACH; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927638065     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1950     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006;12:17-20.
3. Johnson SM, Evers BM. Translational research in gastric malignancy. Surg Oncol Clin N Am 2008;17:323-40, viii.
4. Kim K, Chun KH, Suh PG, Kim IH. Alterations in cell proliferation related gene expressions in gastric cancer. Crit Rev Eukaryot Gene Expr 2011;21: 237-54.
5. Kim DH. Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer. Yonsei Med J 2007;48:694-700.
6. Liang B, Wang S, Yang X, Ye Y, Yu Y, Cui Z. Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer. Chin Med J 2003;116:20-3.
7. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
8. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66.
9. Wright RH, Castellano G, Bonet J, Le Dily F, Font-Mateu J, Ballare C, et al. CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev 2012;26:1972-83.
10. Yang S, Zhang L, Liu M, Chong R, Ding SJ, Chen Y, et al. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res 2013;73:6722-33.
11. Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med 2013;5:999-1018.
12. Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/ CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013;23:618-33.
13. Radomska HS, Alberich-Jorda M, Will B, Gonzalez D, Delwel R, Tenen DG. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPalpha. J Clin Invest 2012;122:2955-66.
14. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013;19:5320-8.
15. Rader J, Russell MR, Hart LS, NakazawaMS, Belcastro LT, Martinez D, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013;19:6173-82.
16. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008;132:487-98.
17. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45.
18. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050-4.
19. Hellmich MR, Pant HC, Wada E, Battey JF. Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc Natl Acad Sci U S A 1992;89:10867-71.
20. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol 2001;2: 749-59.
21. Tsai LH, Delalle I, Caviness VS Jr., Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994;371:419-23.
22. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, et al. A brain-specific activator of cyclin-dependent kinase 5. Nature 1994;371:423-6.
23. Cruz JC, Tsai LH. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 2004;14:390-4.
24. Hawasli AH, Bibb JA. Alternative roles for Cdk5 in learning and synaptic plasticity. Biotechnol J 2007;2:941-8.
25. Hisanaga S, Endo R. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J Neurochem 2010;115: 1309-21.
26. Zhang J, Li H, Zhou T, Zhou J, Herrup K. Cdk5 levels oscillate during the neuronal cell cycle: Cdh1 ubiquitination triggers proteosome-dependent degradation during S-phase. J Biol Chem 2012;287:25985-94.
27. Zhang J, Herrup K. Nucleocytoplasmic Cdk5 is involved in neuronal cell cycle and death in post-mitotic neurons. Cell Cycle 2011;10:1208-14.
28. Zhang J, Li H, Yabut O, Fitzpatrick H, D'Arcangelo G, Herrup K. Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci 2010;30:5219-28.
29. Zhang J, Li H, Herrup K. Cdk5 nuclear localization is p27-dependent in nerve cells: implications for cell cycle suppression and caspase-3 activation. J Biol Chem 2010;285:14052-61.
30. Zhang J, Cicero SA, Wang L, Romito-Digiacomo RR, Yang Y, Herrup K. Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons. Proc Natl Acad Sci U S A 2008;105:8772-7.
31. Zhang J, Herrup K. Cdk5 and the non-catalytic arrest of the neuronal cell cycle. Cell Cycle 2008;7:3487-90.
32. Sandal T, Stapnes C, Kleivdal H, Hedin L, Doskeland SO. A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells. J Biol Chem 2002;277: 20783-93.
33. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, et al. Cyclindependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006;66:7509-15.
34. Lin H, Chen MC, Chiu CY, Song YM, Lin SY. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J Biol Chem 2007;282:2776-84.
35. Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci U S A 2008;105:7570-5.
36. Mao L, Yang Y. Targeting the nuclear transport machinery by rational drug design. Curr Pharm Des 2013;19:2318-25.
37. Niu M, Wu S, Mao L, Yang Y. CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic 2013;14:1042-52.
38. Liu Y, Zhao L, Li W, Zhao D, Song M, Yang Y. FIPSDock: a new molecular docking technique driven by fully informed swarm optimization algorithm. J Comput Chem 2013;34:67-75.
39. Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu DX, et al. CDK5 is essential forTGF-beta1- induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep 2013;3:2932.
40. Pozo K, Castro-Rivera E, Tan C, Plattner F, SchwachG, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell 2013;24:499-511.
41. Hsu FN, Chen MC, Lin KC, Peng YT, Li PC, Lin E, et al. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser(7)(2)(7) on STAT3 in prostate cancer cells. Am J Physiol Endocrinol Metab 2013;305:E975-86.
42. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, et al. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell 2012;23:2856-66.
43. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010;70:4460-9.
44. Lees E. Cyclin dependent kinase regulation. Curr Opin Cell Biol 1995;7: 773-80.
45. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.